Mojgan Morvaridzadeh

Ms. Mojgan Morvaridzadeh

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
MMMojgan Morvaridzadeh
Mojgan Morvaridzadeh
NZNada Zoubdane
Nada Zoubdane
JHJavad Heshmati
Javad Heshmati
MAMehdi ALAMI
Mehdi ALAMI
HBHicham Berrougui
Hicham Berrougui
Abdelouahed KhalilAbdelouahed Khalil
Abdelouahed Khalil
Cardiovascular diseases (CVDs) have become the leading global cause of mortality, prompting a heightened focus on identifying precise indicators for their assessment and treatment. In this perspective, the plasma levels of HDL have emerged as a pivotal focus, given the demonstrable correlation between plasma levels and cardiovascular events, rendering them a noteworthy biomarker. However, it is crucial to acknowledge that HDLs, while intricate, are not presently a direct therapeutic target, necessitating a more nuanced understanding of their dynamic remodeling throughout their life cycle. HDLs exhibit several anti-atherosclerotic properties that define their functionality. This functionality of HDLs, which is independent of their concentration, may be impaired in certain risk factors for CVD. Moreover, because HDLs are dynamic parameters, in which HDL particles present different atheroprotective properties, it remains difficult to interpret the association between HDL level and CVD risk. Besides the antioxidant and anti-inflammatory activities of HDLs, their capacity to mediate cholesterol efflux, a key metric of HDL functionality, represents the main anti-atherosclerotic property of HDL. In this review, we will discuss the HDL components and HDL structure that may affect their functionality and we will review the mechanism by which HDL mediates cholesterol efflux. We will give a brief examination of the effects of aging and diet on HDL structure and function.

1 January 2021 in Clinical Nutrition Research
Verified
Journal Article
Open access
PDF file
MMMojgan Morvaridzadeh
Mojgan Morvaridzadeh
MNMostafa Nachvak
Mostafa Nachvak
RMReza Mohammadi
Reza Mohammadi
SMShima Moradi
Shima Moradi
RMRoghayeh Mostafai
Roghayeh Mostafai
HAHadi Abdollahzad
Hadi Abdollahzad
Morvaridzadeh M, et al. Clin Nutr Res. 2021 Jan;10(1):36-47. https://doi.org/10.7762/cnr.2021.10.1.36

22 November 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
MAMehdi Alami
Mehdi Alami
KBKaoutar Boumezough
Kaoutar Boumezough
Abdelouahed KhalilAbdelouahed Khalil
Abdelouahed Khalil
MRMhamed Ramchoun
Mhamed Ramchoun
SBSamira Boulbaroud
Samira Boulbaroud
HBHicham Berrougui
Hicham Berrougui
Modern research achievements support the health-promoting effects of natural products and diets rich in polyphenols. Pomegranate (PG) (Punica granatum L.) contains a considerable number of bioactive compounds that exert a broad spectrum of beneficial biological activities, including antimicrobial, antidiabetic, antiobesity, and atheroprotective properties. In this context, the reviewed literature shows that PG intake might reduce insulin resistance, cytokine levels, redox gene expression, blood pressure elevation, vascular injuries, and lipoprotein oxidative modifications. The lipid parameter corrective capabilities of PG-ellagitannins have also been extensively reported to be significantly effective in reducing hyperlipidemia (TC, LDL-C, VLDL-C, and TAGs), while increasing plasma HDL-C concentrations and improving the TC/HDL-C and LDL-C/HDL-C ratios. The health benefits of pomegranate consumption seem to be acheived through the amelioration of adipose tissue endocrine function, fatty acid utilization, GLUT receptor expression, paraoxonase activity enhancement, and the modulation of PPAR and NF-κB. While the results from animal experiments are promising, human findings published in this field are inconsistent and are still limited in several aspects. The present review aims to discuss and provide a critical analysis of PG’s bioeffects on the components of metabolic syndrome, type-2 diabetes, obesity, and dyslipidemia, as well as on certain cardiovascular-related diseases. Additionally, a brief overview of the pharmacokinetic properties, safety, and bioavailability of PG-ellagitannins is included.

16 July 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
MMMojgan Morvaridzadeh
Mojgan Morvaridzadeh
MAMehdi ALAMI
Mehdi ALAMI
NZNada Zoubdane
Nada Zoubdane
HSHawa Sidibé
Hawa Sidibé
HBHicham Berrougui
Hicham Berrougui
Abdelouahed KhalilAbdelouahed Khalil
Abdelouahed Khalil
Cardiovascular disease (CVD), particularly atherosclerotic cardiovascular disease (ASCVD), is the leading cause of death worldwide, driven by factors like oxidative stress, inflammation, and lipid metabolism disorders. Although phenolic compounds such as Tyrosol (Tyr) and Hydroxytyrosol (HTyr) found in extra virgin olive oil (EVOO) have shown promising antioxidant and anti-inflammatory effects, their specific roles in modulating oxidative stress biomarkers and high-density lipoprotein (HDL) functionality in elderly populations, especially in those with prior myocardial infarction, are not fully understood. This study aimed to investigate the effects of EVOO phenolic compounds on oxidative stress biomarkers and HDL functionality, and related metabolic outcomes in both healthy and post-myocardial infarction (post-MI) elderly individuals. This pilot randomized clinical trial study included healthy and post-MI participants aged 65–85 years. Participants in each group were randomly assigned to consume 25 mL per day of one of three types of olive oils: high phenolic (HTyr/Tyr) extra virgin olive oil (HP-EVOO), extra virgin olive oil (EVOO), or refined olive oil (ROO) for a period of 26 weeks. Blood samples were collected at baseline and post-intervention to assess key biomarkers. Plasma levels of (poly)phenols, malondialdehyde (MDA), total antioxidant capacity (FRAP), lecithin-cholesterol acyltransferase activity (LCAT), and serum paraoxonase-1 (PON-1) activity were measured. A total of 34 individuals completed the study (mean age: 74 years). Baseline characteristics, including sex, age, body mass index (BMI), weight, blood pressure, and inflammatory markers like C-reactive protein (CRP) levels, did not differ significantly between the two groups. A significant increase in both FRAP levels and PON-1 activity was observed in post-MI participants following HP-EVOO consumption compared to baseline (p = 0.014). No significant changes were observed in MDA levels, LCAT activity, or plasma (poly)phenols. These results indicate that HP-EVOO may enhance antioxidant capacity, particularly FRAP and PON-1 activity, in elderly post-MI individuals. The observed differences between groups suggest that underlying cardiometabolic status may influence the response to olive oil phenolic compounds. Further studies are needed to explore the long-term cardiovascular effects.

2 December 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
MMMojgan Morvaridzadeh
Mojgan Morvaridzadeh
MAMehdi ALAMI
Mehdi ALAMI
HBHicham Berrougui
Hicham Berrougui
KBKaoutar Boumezough
Kaoutar Boumezough
HSHawa Sidibé
Hawa Sidibé
Abdelouahed KhalilAbdelouahed Khalil
Abdelouahed Khalil
Atherosclerosis is a chronic inflammatory cardiovascular disease that may result from the interaction between oxidative stress, immune dysregulation, and metabolic disorders. Recent studies indicate that the well-known phenolic compounds, hydroxytyrosol (HTyr) and tyrosol (Tyr) present in extra virgin olive oil, confer cardioprotection through various mechanisms of action that include antioxidant, anti-inflammatory, and metabolic regulatory properties. The gut microbiota modulates the structure, bioavailability, and bioactivity of these phenolic compounds, thereby influencing their therapeutic potential. This review explores the intricate interactions between Tyr, HTyr, and gut microbiota within the context of atherosclerosis prevention and management. We explore how gut microbial metabolism can magnify or alter the biological effects of the Tyr and HTyr, and how interindividual differences in microbiota composition may influence their efficacy. A deeper understanding of these mechanisms could support the development of precision nutrition strategies aimed at reducing the risk of atherosclerosis.

24 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MMMojgan Morvaridzadeh
Mojgan Morvaridzadeh
MAMehdi ALAMI
Mehdi ALAMI
NZNada Zoubdane
Nada Zoubdane
HSHawa Sidibé
Hawa Sidibé
HBHicham Berrougui
Hicham Berrougui
Abdelouahed KhalilAbdelouahed Khalil
Abdelouahed Khalil
Cardiovascular disease (CVD), particularly atherosclerotic cardiovascular disease (ASCVD), is the leading cause of death worldwide, driven by factors like oxidative stress, inflammation, and lipid metabolism disorders. Although phenolic compounds such as Tyrosol (Tyr) and Hydroxytyrosol (HTyr) found in extra virgin olive oil have shown promising antioxidant and anti-inflammatory effects, their specific roles in modulating oxidative stress biomarkers and HDL functionality in elderly populations, especially in those with prior myocardial infarction, are not fully understood. This study aimed to investigate the effects of EVOO phenolic compounds on oxidative stress biomarkers and HDL functionality, and related metabolic outcomes in both healthy and post-MI elderly individuals. This pilot randomized clinical trial study included healthy and post-myocardial infarction (pos-MI) participants aged 65-85 years. Participants in each group were randomly assigned to consume 25 ml per day of one of three types of olive oils: high HTyr/Tyr extra virgin olive oil (HP-EVOO), extra virgin olive oil (EVOO), or refined olive oil (ROO) for a period of 26 weeks. Blood samples were collected at baseline and post-intervention to assess key biomarkers. Plasma levels of (poly)phenols, malondialdehyde (MDA), total antioxidant capacity (FRAP), lecithin-cholesterol acyltransferase activity (LCAT) and serum paraoxonase-1 (PON-1) activity were measured. A total of 34 individuals completed the study (mean age: 74 years). Baseline characteristics, including sex, age, body mass index (BMI), weight, blood pressure, and inflammatory markers like C-reactive protein (CRP) levels, did not differ significantly between the two groups. A significant increase in both FRAP levels and PON-1 activity was observed in post-MI participants following HP-EVOO consumption compared to baseline (p = 0.014). No significant changes were observed in MDA levels, LCAT activity, or plasma (poly)phenols. These results indicate that HP-EVOO may enhance antioxidant capacity, particularly FRAP and PON-1 activity, in elderly post-MI individuals. The observed differences between groups suggest that underlying cardiometabolic status may influence the response to olive oil phenolic compounds. Further studies are needed to explore the long-term cardiovascular effects.